Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer By Ogkologos - April 23, 2026 174 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-ov65/KEYNOTE-B96 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Factors Associated with COVID-19 Severity Among Patients with Cancer March 22, 2021 Pharmacy services are an untapped resource in tackling nation’s major health... July 12, 2022 A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials May 7, 2019 New hormone treatment for advanced prostate cancer made available in England June 8, 2021 Load more HOT NEWS Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With... How Fatty Liver Disease Helps Cancer Thrive in the Liver Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients...
